Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Casina Kan"'
Autor:
Philippe Clézardin, Marie Brevet, Antoine E. Karnoub, Géraldine Aimond, Clémence Thomas, Floriane Pez, Edith Bonnelye, Martine Croset, Casina Kan, Paola Di Mauro, Laura Ferreras, Caroline Reynaud
Supplementary figure legends from S1 to S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::506b681f51e3e63df29d3c1cd4edea61
https://doi.org/10.1158/0008-5472.22411913.v1
https://doi.org/10.1158/0008-5472.22411913.v1
Autor:
Philippe Clézardin, Marie Brevet, Antoine E. Karnoub, Géraldine Aimond, Clémence Thomas, Floriane Pez, Edith Bonnelye, Martine Croset, Casina Kan, Paola Di Mauro, Laura Ferreras, Caroline Reynaud
Supplementary Table S1. Primer pairs used for quantitative real-time PCR analysis. Supplementary Table S2. Summary of the gene expression datasets used for meta-analysis. Supplementary Table S3. Expression levels of LOX-like mRNAs in Hct116 cells tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41cb0f506b1611ac8ebf2bea535cb7aa
https://doi.org/10.1158/0008-5472.22411907.v1
https://doi.org/10.1158/0008-5472.22411907.v1
Autor:
Philippe Clézardin, Marie Brevet, Antoine E. Karnoub, Géraldine Aimond, Clémence Thomas, Floriane Pez, Edith Bonnelye, Martine Croset, Casina Kan, Paola Di Mauro, Laura Ferreras, Caroline Reynaud
Lysyl oxidase (LOX) is a secreted copper-dependent amine oxidase whose primary function is to drive collagen crosslinking and extracellular matrix stiffness. LOX in colorectal cancer synergizes with hypoxia-inducible factor-1 (HIF-1) to promote tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fa6ac9faf7030fa3eb06539061a20c7
https://doi.org/10.1158/0008-5472.c.6508325.v1
https://doi.org/10.1158/0008-5472.c.6508325.v1
Autor:
Philippe Clézardin, Marie Brevet, Antoine E. Karnoub, Géraldine Aimond, Clémence Thomas, Floriane Pez, Edith Bonnelye, Martine Croset, Casina Kan, Paola Di Mauro, Laura Ferreras, Caroline Reynaud
Figure S1: LOX expression and clinical outcomes. Figure S2:The LOX inhibitor βAPN inhibits osteolytic lesion formation in vivo. Figure S3: Measurement of LOX enzymatic activity. Figure S4: Correlation analysis of the expression intensity of LOX and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed28ac88e4401f5ca74264c0790f9bf
https://doi.org/10.1158/0008-5472.22411910.v1
https://doi.org/10.1158/0008-5472.22411910.v1
Autor:
Alexander Dobrovic, Catherine A.B. Saunders, Rosemary L. Balleine, Yoke-Eng Chiew, Ann-Marie Patch, Bo Gao, Paul R. Harnett, Russell Hogg, John V. Pearson, Nicola Waddell, David D.L. Bowtell, Sivatharsny Srirangan, Casina Kan, Sean M. Grimmond, Gerard Wain, Sian Fereday, Dariush Etemadmoghadam, Anna deFazio, Tania Moujaber, Catherine J. Kennedy, Nadia Traficante
Purpose Low-grade serous ovarian carcinoma (LGSC) responds poorly to chemotherapy and is characterized by activating mutations in the Ras sarcoma–mitogen-activated protein kinase (RAS-MAPK) pathway, including oncogenic BRAF. However, response to BR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dcc106389643a2a29fa16711b88e2c1
https://hdl.handle.net/2123/20486
https://hdl.handle.net/2123/20486
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 34(6)
Postmenopausal osteoporosis is characterized by the occurrence of fragility fracture with an increase in morbidity and mortality. Recently, microRNAs (miRNAs) have raised interest as regulators of translational repression, mediating a number of key p
Publikováno v:
Genes, Chromosomes and Cancer. 54:1-19
Ovarian cancer is the fifth most common cause of cancer death in women worldwide. Serous epithelial ovarian cancer (SEOC) is the most common and aggressive histological subtype. Widespread genomic alterations go hand-in-hand with aberrant DNA damage
Autor:
Claire Benetollo, Edith Bonnelye, Vincenzo Castronovo, Jennifer Rieusset, Thomas J. Rosol, Mathilde Bouchet, Anais Fradet, Akeila Bellahcene, Lamia Bouazza, Carine Delliaux, Philippe Clézardin, Martine Duterque-Coquillaud, Martine Croset, Casina Kan, Francesco Pantano, Xavier Leroy, Manon Gervais, Jane E. Aubin, Geoffrey Vargas, Yohann Bala
Publikováno v:
Oncotarget
Oncotarget, Impact journals, 2016, 7 (47), pp.77071-77086. ⟨10.18632/oncotarget.12787⟩
Oncotarget, 2016, 7 (47), pp.77071-77086. ⟨10.18632/oncotarget.12787⟩
Oncotarget, Impact journals, 2016, 7 (47), pp.77071-77086. ⟨10.18632/oncotarget.12787⟩
Oncotarget, 2016, 7 (47), pp.77071-77086. ⟨10.18632/oncotarget.12787⟩
International audience; Bone metastases are one of the main complications of prostate cancer and they are incurable. We investigated whether and how estrogen receptor-related receptor alpha (ERRalpha) is involved in bone tumor progression associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0c51bc67b6222c2f5b71c8a281298a9
Autor:
Martine Croset, Francesco Pantano, Casina Kan, Edith Bonnelye, Francoise Descotes, Catherine Alix-Panabières, Charles Lecellier, Richard Bachelier, Nathalie Allioli, Saw See Hong, Kai Bartkowiak, Klaus Pantel, Philippe Clézardin
Publikováno v:
Cancer Research. 78:486-486
MicroRNAs (miRNAs), which are master regulators of gene expression, have emerged as key players in cancer metastasis. Here, we established miR-30 family members (miR-30a, miR-30b, miR-30c, miR-30d and miR-30e) as breast cancer bone metastasis suppres
Autor:
Tania Moujaber, Dariush Etemadmoghadam, Cristina Mapagu, Catherine Kennedy, Yoke-Eng Chiew, Casina Kan, Nikilyn Nevins, Sivatharsny Srirangan, Sian Fereday, Nadia Traficante, Australian Ovarian Cancer Study group, David Bowtell, Rosemary Balleine, Paul Harnett, Anna deFazio
Publikováno v:
Cancer Research. 78:2584-2584
Low-grade serous ovarian cancer (LGSC) responds poorly to platinum based chemotherapy and is characterized by activating RAS-MAPK pathway mutations, including oncogenic BRAF. Drugs that target this pathway are effective in BRAF-mutant melanoma but ot